Biorevolution, Artificial Intelligence, Large Language Models, Scientific Revolution, Future Medicine
Louise von Stechow
Epsiode 27: AI in drug development – Expanding ...

In episode 27 of We’re doomed, We’re saved , the bio revolution podcast  Andreas Horchler and Louise von Stechow talk about the potential of Artificial Intelligence (AI) in drug discovery and development. The pharma industry is struggling with high development costs and failure rates. Can AI help to overcome those challenges, and what is hype and what is reality?

Epsiode 27: AI in drug development – Expanding the option space
Biorevolution, Artificial Intelligence, Large Language Models, Scientific Revolution, Future Medicine
Louise von Stechow
Epsiode 26: The future of medicine - trends, ...

In episode 26 of We’re doomed we’re saved we talk about the future trends in medicine, such as technologization, virtualization, predictive orientation and patient centration. These trends are corroborated by new technologies, such as artificial intelligence (AI), telemedicine, wearable devices and smart sensors.
Listen to We're doomed, We're saved, the bio revolution podcast with Andreas Horchler and Louise von Stechow here.

Epsiode 26: The future of medicine - trends, technologies and skills
Biorevolution, Artificial Intelligence, Large Language Models
Louise von Stechow
Epsiode 25: 1.5 years of LLMs - hope, hype and ...

In episode 25 of We’re doomed we’re saved we talk to idalab founder and mathematician, Paul von Bünau we discuss the promise and challenges of Large Language Models (LLMs) in the biomedical field and ask the question if we can ever stop them from hallucinating.

Epsiode 25: 1.5 years of LLMs - hope, hype and hallucination
Artificial Intelligence, Rare Disease
Louise von Stechow
Epsiode 24: Artificial intelligence - hope for ...

Rare or orphan diseases affect only a small percentage of the population and often lack effective treatments. While rare individually, in total, more than 350 million people worldwide live with rare diseases. Many of these are very hard to diagnose, let alone cure, and the rarity of patients challenges the development of novel treatments.

To make the development of drugs for rare diseases more efficient and successful, artificial intelligence (AI) could be an important ally not only for drug makers but also for patients.

Epsiode 24: Artificial intelligence - hope for rare desease patients?
Scientific Revolution, Biorevolution
Louise von Stechow
Epsiode 23: New biotechnologies: revolution or ...

A revolution driven by novel biotechnologies (gene editing, neuroprosthetics, synthetic biology, and artificial intelligence in biotech) has the potential to not only change the way we live but the very foundations of our lives – our biology.

But is the so-called biorevolution a real "scientific revolution"?

In the new episode of "We're Doomed, We're Saved," Andreas Horchler and Louise von Stechow look at the biorevolution from different angles, examining its transformative potential and comparing it to revolutions that came before.

Epsiode 23: New biotechnologies: revolution or evolution?

CRISPR CAS

Epsiode 19: mRNA Therapeutics - New applications for an old molecule

RNA, one of the oldest and most versatile biomolecules, has recently entered the therapeutic arena. While for many observers the success of mRNA vaccines seemed to come out of the blue, its build on the fundament of research that has large gone ignored.

Now mRNA therapeutics are enjoying the limelight of great economic success for companies like BioNTech / Pfizer and Moderna, and the awarding of the 2023 Nobel Prize to two mRNA researchers. But with the fame also comes a huge public backlash of anti-vaxxers who fear the perceived novelty of mRNAs.

In the 19th episode of We're doomed, we're saved Louise von Stechow and Andreas Horchler talk with their guest, mRNA researcher Lucia Lapazio who has known the field before and after the hype.

Content and Editing: Louise von Stechow und Andreas Horchler

Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.

Image: s-ASFul4w-o58- via Unsplash

Epsiode 18: Ozempic & co – a new era of weight loss?

In principle the solution to the problem of overweight should be very easy:

eat less and exercise more.But anyone who’s ever tried to lose weight – so probably almost anyone – will be able to testify that things are not as simple. So now Ozempic enters the scene, a diabetes drug that looks like a gamechanger in the big business of weight loss.

In episode 18 of We're doomed we're saved, Andreas Horchler and Louise von Stechow discuss the history of weight loss pills and the medical and cultural reasons why we (think we) need to be thin.

Content and Editing: Louise von Stechow und Andreas Horchler

Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.

Nathan Dumlao- via Unsplash

Epsiode 17: CRISPR CAS – Life’s processing tool

Gene editing technology allows humans, for the first time, to change the code of life with a precise editing system offering the potential for curing genetic diseases. The gene editing field is moving with impressive speed: after the seminal paper on the technology was published in 2012, the Nobel Prize awarded for the technology in 2020, and the first therapy approved for treatment of blood diseases in 2023.

In this episode of We’re doomed, we’re saved Andreas Horchler and Louise von Stechow, discuss the tremendous potential of the technology, but also its darker side – the high cost of the therapeutic applications and the potential for augmenting, altering, and redesigning human genomes.

Content and Editing: Louise von Stechow und Andreas Horchler

Disclaimer: Louise von Stechow, Andreas Horchler and their guests express their personal opinions, which are founded on research on the respective topics, but do not claim to give medical, investment or even life advice in the podcast.

Image: Vipul Jha- via Unsplash